Boston Scientific Target of Unusually Large Options Trading (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of unusually large options trading activity on Wednesday. Stock traders acquired 23,490 put options on the stock. This is an increase of 52% compared to the average volume of 15,480 put options.

Boston Scientific Trading Down 13.3%

Shares of BSX stock traded down $12.22 during trading hours on Wednesday, reaching $79.40. The company had a trading volume of 39,472,826 shares, compared to its average volume of 13,884,696. Boston Scientific has a 1-year low of $75.00 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The firm has a market cap of $117.71 billion, a price-to-earnings ratio of 42.63, a P/E/G ratio of 1.63 and a beta of 0.67. The company has a 50 day moving average of $94.89 and a 200 day moving average of $99.29.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period last year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.

Analyst Ratings Changes

BSX has been the subject of a number of recent research reports. UBS Group reissued a “buy” rating on shares of Boston Scientific in a report on Wednesday, December 17th. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, January 21st. The Goldman Sachs Group reaffirmed a “buy” rating and set a $112.00 price objective on shares of Boston Scientific in a research note on Friday, January 9th. TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a research note on Monday. Finally, BTIG Research reiterated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $123.26.

Insider Buying and Selling

In other news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 191,105 shares of company stock valued at $18,067,697. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Riverwater Partners LLC raised its position in shares of Boston Scientific by 3.3% in the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after buying an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management boosted its position in Boston Scientific by 3.8% in the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 99 shares in the last quarter. Crown Wealth Group LLC grew its stake in shares of Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after buying an additional 100 shares during the last quarter. Claret Asset Management Corp increased its holdings in shares of Boston Scientific by 4.4% during the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after buying an additional 102 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its holdings in shares of Boston Scientific by 3.9% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after acquiring an additional 103 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat: BSX posted $0.80 EPS vs. $0.78 consensus and reported 15.9% year-over-year net sales growth — confirms underlying demand and operational momentum. Zacks: Boston Scientific Beats Q4
• Positive Sentiment: Revenue detail: net sales ~$5.29B with ~12.7% organic growth — supports medium-term revenue base and validates product momentum across several franchises. PR Newswire: Q4 Results
• Neutral Sentiment: Analyst backdrop: many firms still rate BSX a Buy with mid- to high‑teens upside targets — consensus remains constructive despite near-term headwinds. MarketBeat: Analyst Consensus
• Negative Sentiment: Soft 2026 guidance: management issued modest revenue growth and profit guidance that trailed Street expectations, which was the primary driver of the early selloff. WSJ: Profit, Sales Rise but Issues Soft Guidance
• Negative Sentiment: Electrophysiology weakness: management called out light EP sales (one of its key growth drivers), raising near-term execution concerns. Blockonomi: Why Shares Dropped
• Negative Sentiment: Market positioning and sentiment: unusually large put-option buying (≈23,490 puts, ~52% above average) indicates elevated bearish hedging/speculation adding downward pressure.
• Negative Sentiment: Insider sale: CEO Michael Mahoney sold ~160,901 shares (~$15M) last week; such a large disclosed sale can amplify negative sentiment even if preplanned. SEC Filing: Insider Sale

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.